Custom biotin-modified LNP development for SMVT-targeted delivery to biotin receptor-expressing cells.
Biotin-conjugated lipid nanoparticles, also known as biotin-LNPs or Bio-LNPs, are LNP delivery systems engineered with biotin (vitamin B7) or biotin-bearing lipid conjugates displayed on the particle surface. The displayed biotin ligands on these biotin-LNPs bind to SMVT (encoded by SLC5A6) with high affinity, enabling receptor-mediated active targeting and internalization in SMVT-positive tumor cell models, activated macrophages, and multidrug-resistant cancer cell lines for targeted delivery of drugs, probes, and other molecules.
BOC Sciences supports targeted LNP development for SMVT-oriented delivery projects. Our services cover biotin ligand design, biotin-lipid conjugate preparation, LNP surface engineering, payload-compatible formulation development, physicochemical characterization, and SMVT+ cell uptake and functional evaluation. We help build biotin-modified LNP systems for the delivery of siRNA, mRNA, circRNA, chemotherapeutic agents, chemosensitizers, proteins, peptides, and other payloads to target SMVT-expressing cells and tissues, supporting therapeutic research, mechanism studies, imaging, and other diverse applications.
Biotin Conjugated LNP Surface Structure DiagramBOC Sciences provides an integrated biotin-LNP development workflow from biotin ligand engineering and LNP preparation to surface characterization, receptor-specific uptake evaluation, and payload function analysis.
Biotin-lipid conjugates serve as molecular anchors that present biotin on the LNP surface, with linker length and valency tuned for optimal SMVT accessibility.
Payload-loaded LNP cores are prepared as carrier platforms, with encapsulation efficiency and particle quality directly influencing the performance of the final biotin-LNP system.
The coupling strategy determines surface biotin density, particle stability, and the flexibility to adapt targeting configurations for different research needs.
Physicochemical and cell-based assays confirm successful biotin surface modification and functional payload delivery to SMVT-expressing cells.
BOC Sciences develops biotin-modified LNPs using structure-guided ligand engineering and formulation-compatible surface modification strategies. Depending on the project goal, we can help select monovalent biotin, multivalent biotin clusters, PEG-bridged biotin lipids, or avidin-biotin modular assembly.
Biotin ligands can be designed in different structural formats. BOC Sciences helps clients select a suitable biotin ligand based on receptor expression level, target cell model, payload type, surface exposure needs, and formulation stability.
| Biotin Ligand Option | What It Means | Why Use It | Typical Research Uses |
|---|---|---|---|
| Monovalent Biotin | One biotin molecule connected to one lipid anchor, usually through a PEG linker. | Simple structure, easy to introduce into LNPs, and suitable for initial SMVT-targeting studies. | Basic SMVT+ cell uptake studies, early feasibility screening, and comparison with unmodified LNPs. |
| Divalent Biotin, Bio2 | Two biotin molecules displayed on one branched linker or dual-arm biotin-lipid structure. | Provides stronger SMVT interaction than single biotin display in some receptor-rich cell models. | SMVT-high tumor cell uptake studies, receptor-density comparison, and improved targeting screening. |
| Multivalent Biotin, Bio4-Bio8 | Multiple biotin molecules arranged on a dendritic, branched, or polymer-like scaffold. | Increases the chance of SMVT binding through multivalent interaction, especially in high-expression models. | High-SMVT tumor models, tumor spheroid uptake studies, and intensive ligand-density optimization. |
| Biotin-PEG-Lipid Ligands | Biotin is connected to a lipid anchor through a PEG spacer, such as Bio-PEG2000-DSPE or short-chain Bio-PEG-lipid. | PEG works as a flexible arm that extends biotin from the LNP surface and helps SMVT recognize it. | Most biotin-LNP surface modification projects, including siRNA, mRNA, small molecule, and imaging payload delivery. |
| Biotin-Cholesterol Ligands | Biotin is connected to cholesterol or a cholesterol-like lipid anchor for insertion into the LNP lipid layer. | Useful for mild post-insertion or rapid surface modification of preformed LNPs. | Fast feasibility testing, post-insertion screening, and comparison with phospholipid-anchored biotin ligands. |
| Avidin-Biotin Modular Ligands | Streptavidin, NeutrAvidin, or avidin bridges biotin on the LNP surface with biotinylated targeting molecules. | Exploits the ultra-high affinity of avidin-biotin (KD ~10-15 M) for stable, rapid assembly. | Rapid ligand display screening, dual-targeting proof-of-concept, and modular surface engineering. |
We develop biotin incorporation methods according to payload sensitivity, expected biotin orientation, reaction compatibility, and the required level of surface control.
| Coupling Strategy | Service Subtype | Chemical Principle | Suitable Use Cases |
|---|---|---|---|
| Lipid Anchoring | Biotin-cholesterol insertion | Biotin-cholesterol is inserted into the LNP lipid layer through hydrophobic interaction. | Rapid and mild modification for early feasibility screening. |
| Biotin-DSPE/DSPC co-assembly | Biotin-phospholipids participate in LNP assembly as structural lipid components. | Stable biotin display and more controllable orientation during formulation development. | |
| PEG Bridging | Bio-PEG2000-DSPE post-insertion | PEG spacer provides flexibility and spatial separation from the LNP surface. | Common route for balancing particle stability and SMVT accessibility. |
| Bio-PEG54-DSPE short-chain bridging | Short PEG reduces excessive shielding and keeps biotin closer to the particle surface. | Useful for high-density biotin display and tumor penetration-oriented studies. | |
| Avidin-Biotin Affinity | Streptavidin bridging | Streptavidin binds biotin on LNPs and biotinylated ligands with ultra-high affinity. | Modular dual-targeting and rapid surface modification screening. |
| NeutrAvidin bridging | NeutrAvidin offers similar affinity with reduced carbohydrate content. | Applications where minimized non-specific binding is preferred. | |
| Covalent Coupling | Thiol-maleimide coupling | Biotin-thiol reacts with Mal-PEG-lipid displayed on the LNP surface. | Selective surface conjugation when reaction pH and ligand input are controlled. |
| DBCO-azide copper-free click chemistry | Biotin-azide reacts with DBCO-PEG-lipid on the LNP surface. | Bioorthogonal conjugation for surface-modified LNP screening. |
Develop biotin-modified LNPs with optimized biotin exposure, payload loading, particle quality, SMVT-oriented uptake evaluation, and functional delivery readouts.
Biotin-modified LNPs use a small vitamin-derived ligand to guide lipid nanoparticles toward cells that overexpress SMVT. This approach combines deep tissue penetration with payload versatility, offering a practical path for targeted delivery of RNA therapeutics, chemotherapeutic agents, and imaging probes.
Small Ligand, High Affinity, Deep Tumor Reach
At 244 Da, biotin is roughly 250 times smaller than a typical antibody. This compact size matters in dense tumor tissue, where large ligands are physically blocked from reaching cells deep in the mass. Biotin binds SMVT with nanomolar affinity, so even low surface density achieves meaningful uptake. The chemistry is fully synthetic, giving you batch-to-batch consistency and straightforward quality control by HPLC and mass spectrometry, without the cost and variability of biological production.
Overcoming Multidrug Resistance
SMVT is overexpressed on many multidrug-resistant (MDR) cancer cell lines, including MCF-7/ADR breast cancer cells with high P-glycoprotein (P-gp) expression. By delivering chemotherapeutic agents and chemosensitizers simultaneously through biotin-LNPs, research teams can bypass P-gp efflux pumps and restore drug sensitivity in resistant tumors. This dual-payload strategy transforms biotin-LNPs from a simple targeting tool into a functional MDR reversal platform.
Same Surface, Different Payloads
Biotin modification does not lock you into one cargo type. The same engineering strategy works for siRNA, mRNA, circRNA, chemotherapeutic drugs, chemosensitizers, proteins, peptides, and imaging probes. This means you can pivot from an RNA program to a combination chemotherapy or imaging study without rebuilding your delivery platform from the ground up.
Repeat Dosing Without Immunogenicity Risk
Biotin is an essential endogenous vitamin with established metabolic pathways. Unlike protein-based targeting ligands, it carries no risk of triggering anti-drug antibodies (ADA), which can neutralize efficacy. This makes biotin-LNPs suitable for chronic dosing regimens and combination therapies where repeated administration is essential for research outcomes.
BOC Sciences develops biotin-modified LNPs for different payload types used in SMVT-targeted delivery research. We help match each payload with suitable biotin surface design, LNP formulation strategy, and SMVT+ cell evaluation model.
| Payload Type | Supported Applications | Request Information |
|---|---|---|
| Biotin-LNPs Development for siRNA | Used for gene silencing in SMVT+ tumor cell models, MDR cancer cell lines, and inflammation-related pathway studies. Typical applications include oncogene knockdown, P-gp expression reduction, apoptosis pathway activation, and target validation in SMVT-overexpressing cell systems. | Inquiry |
| Biotin-LNPs Development for mRNA | Applied to protein expression, immune-modulating factor delivery, tumor cell reprogramming research, macrophage phenotype regulation, and antigen-expression studies in SMVT-expressing cells. Biotin modification helps direct mRNA-loaded LNPs toward selected SMVT+ cell populations. | Inquiry |
| Biotin-LNPs Development for Chemotherapeutic Drug | Suitable for doxorubicin, paclitaxel, gemcitabine, cisplatin, and other agents delivered to SMVT+ tumor cells. Biotin targeting enhances drug accumulation in cancer cells while sparing healthy tissue in research models. | Inquiry |
| Biotin-LNPs Development for Dual-Payload | Designed for co-delivery of chemotherapy drugs and chemosensitizers, siRNA and small molecules, or other combination payloads. These systems support MDR reversal studies and multi-readout formulation evaluation in SMVT+ cell models through LNP co-delivery strategies. | Inquiry |
| Biotin-LNPs Development for circRNA | Used for sustained expression studies, circular RNA delivery evaluation, and receptor-oriented RNA delivery research. Biotin-modified circRNA LNPs can be applied in SMVT+ tumor cell models and long-expression reporter studies. | Inquiry |
| Biotin-LNPs Development for Protein | Applied to intracellular protein delivery, enzyme delivery, antigen delivery, and functional protein transport into SMVT-expressing cells. Biotin modification can help improve cell-selective uptake in SMVT-rich tumor models. | Inquiry |
| Biotin-LNPs Development for Peptide | Used for delivery of functional peptides, antigenic peptides, cell-penetrating peptides, and receptor-related peptide payloads. Biotin-LNPs can support peptide uptake studies in SMVT+ tumor cells and activated macrophage models. | Inquiry |
| Biotin-LNPs Development for Imaging Probe | Used for fluorescent tracking, receptor-mediated uptake visualization, intracellular localization, tumor spheroid penetration, and SMVT-targeting mechanism evaluation. These systems connect formulation design with visible delivery behavior. | Inquiry |
| Biotin-LNPs Development for Custom Payload | Developed for unusual payloads, exploratory delivery systems, early feasibility studies, and project-specific SMVT-targeted applications. BOC Sciences evaluates payload compatibility, biotin surface strategy, particle behavior, and SMVT+ cell delivery performance. | Inquiry |
Biotin-LNP development often faces bottlenecks when biotin display, LNP core formulation, payload loading, SMVT biology, and functional readouts are not evaluated together. BOC Sciences helps clients identify the real source of performance loss.
Weak SMVT+ Cell Uptake Improvement
A biotin-LNP may show limited uptake improvement if the biotin ligand is masked by PEG, displayed at poor density, or placed too close to the LNP surface. We optimize biotin-lipid structure, PEG spacer length, ligand density, and PEG-lipid ratio through LNP PEG-lipid optimization services.
Particle Size Increase After Biotin Modification
Excessive biotin-lipid incorporation can disturb LNP self-assembly and lead to larger particles or broader PDI. We rebalance helper lipids, cholesterol, ionizable lipid systems, PEG-lipids, and biotin-bearing lipids to restore particle uniformity.
Reduced Payload Encapsulation
Biotin-bearing lipids may alter the self-assembly environment required for RNA or drug loading. We optimize lipid composition, aqueous phase conditions, payload input, and processing parameters for nucleic acids encapsulation in LNPs, hydrophobic payload encapsulation, and hydrophilic payload encapsulation.
Unclear SMVT Contribution
SMVT+ cells can internalize nanoparticles through multiple pathways. We design SMVT-high and SMVT-low cell comparisons, free biotin competition, unmodified controls, ligand-density variants, and receptor-related readouts to clarify the targeting contribution.
High Uptake but Weak Payload Function
Strong uptake does not always lead to strong mRNA expression, siRNA knockdown, or drug activity. We evaluate RNA integrity, intracellular localization, endosomal escape, and functional response with LNP endosomal escape evaluation when needed.
MDR Reversal Efficacy Below Expectation
Single chemotherapeutic payload may not overcome P-gp efflux in resistant cells. We design dual-payload biotin-LNPs combining anticancer drugs with chemosensitizers, optimize drug-to-sensitizer ratios, and evaluate synergy in SMVT+ MDR cell models.
BOC Sciences helps research teams troubleshoot biotin ligand exposure, payload encapsulation, particle instability, SMVT-specific uptake, endosomal escape, and functional delivery readouts.
We begin by reviewing your payload type, target cell model, SMVT expression level, preferred readout, expected LNP attributes, and project objective. We clarify whether your study focuses on SMVT+ breast cancer cells, SMVT+ ovarian cancer cells, P-gp-overexpressing MDR lines, activated macrophage models, or other SMVT-expressing systems.
BOC Sciences designs a biotin surface strategy that matches your target cells and payload. The design may include biotin ligand type (monovalent, multivalent), PEG spacer length, lipid anchor, biotin density range, and coupling route. We also support nanoparticle surface functionalization services for surface-engineered delivery systems.
We prepare biotin-LNP candidates using co-assembly, post-insertion, or avidin-biotin bridging strategies. During LNP process optimization, we adjust lipid composition, payload loading, mixing conditions, buffer exchange, biotin density, and particle stability. Matched unmodified LNPs and ligand-free controls can also be prepared for comparison.
Each biotin-LNP candidate is evaluated for particle size, PDI, zeta potential, payload loading, biotin density, and formulation integrity. We can also support nanoparticle cellular uptake testing, intracellular localization, reporter expression, gene silencing, drug activity, release behavior, and distribution-related readouts in suitable research models.
Biotin-modified LNPs leverage SMVT overexpression on tumor cells and activated macrophages to deliver payloads with receptor-level precision. This targeting design spans oncology, multidrug resistance reversal, inflammatory disease, and dual-ligand combination therapy.
Challenge: A research team was developing a biotin-modified LNP to co-deliver doxorubicin (DOX) and quercetin (QUE) into MCF-7/ADR multidrug-resistant breast cancer cells. Their initial formulation showed acceptable drug encapsulation, but the MDR reversal effect was weak. The uptake improvement over unmodified LNP was marginal, and intracellular DOX accumulation remained low due to P-gp efflux. The client needed to determine whether the issue came from insufficient SMVT targeting, suboptimal drug ratio, or poor endosomal release.
Diagnosis: BOC Sciences reviewed the original formulation and identified three issues. First, the monovalent biotin ligand density was too low to generate clear SMVT-mediated uptake. Second, the DOX-to-QUE weight ratio was not optimized for P-gp inhibition synergy. Third, the ionizable lipid system provided limited endosomal escape, trapping payloads in lysosomal compartments after SMVT-mediated internalization.
Solution: BOC Sciences prepared a systematic screening panel. We synthesized Bio-PEG2000-DSPE and compared three biotin densities (low, medium, high) against unmodified controls. For each density level, we screened three DOX:QUE weight ratios (3:1, 2:1, 1:1) and two ionizable lipid balances. Candidate LNPs were evaluated by particle size, PDI, zeta potential, drug loading analysis, biotin surface density, SMVT+/SMVT-low uptake comparison, free biotin competition, intracellular DOX fluorescence, P-gp expression level, and cell viability.
Result: The optimized biotin-LNP maintained an average particle size of about 112 nm with a PDI below 0.18. DOX encapsulation efficiency reached approximately 85% and QUE encapsulation approximately 78%. At a DOX:QUE ratio of 2:1 with medium biotin density, SMVT+ MCF-7/ADR cell uptake improved about 2.8-fold compared with unmodified LNP. Intracellular DOX fluorescence increased about 3.2-fold, P-gp expression decreased about 45%, and cell viability inhibition improved about 2.5-fold versus free DOX at equivalent drug concentration. The client obtained a data-supported formulation for follow-up MDR reversal studies.
Challenge: A biotechnology group wanted to deliver an immune-modulating mRNA payload into SMVT+ ovarian cancer cells (OVCAR-3) using biotin-LNPs. Their monovalent biotin-LNP showed measurable uptake, but the mRNA expression signal was weak and the uptake difference between SMVT-high and SMVT-knockdown cells was not convincing. They needed stronger receptor specificity and higher functional delivery output.
Diagnosis: BOC Sciences found two main issues. First, monovalent biotin display was not strong enough for the selected OVCAR-3 model, which expresses moderate SMVT levels. Second, the formulation showed high particle uptake but insufficient cytosolic mRNA delivery, suggesting that endosomal escape and ionizable lipid balance needed optimization. The PEG-lipid level also likely reduced SMVT accessibility.
Solution: We designed a multivalent biotin ligand panel, including Bio2 and Bio4 display formats, and compared them with the original monovalent biotin-LNP. The screening included ligand density (three levels), PEG spacer length (PEG54 vs. PEG2000), ionizable lipid ratio, and two buffer exchange conditions. Candidate LNPs were evaluated by mRNA integrity, particle attributes, biotin display quantification, OVCAR-3 uptake, SMVT-knockdown cell comparison, free biotin competition, intracellular localization, and reporter expression.
Result: The optimized Bio4-LNP maintained an average particle size of about 105 nm and mRNA encapsulation above 82%. OVCAR-3 cell uptake increased about 2.1-fold compared with the monovalent biotin-LNP, while reporter expression improved about 2.9-fold under the selected in vitro condition. SMVT-knockdown cell uptake dropped about 60%, confirming SMVT-mediated targeting. The client received a data-supported multivalent ligand architecture and formulation strategy for SMVT-oriented ovarian cancer delivery research.
Comprehensive Raw Material SupplyOur in-house inventory covers ionizable lipids, PEG-lipids, helper lipids, cholesterol, biotin-PEG-lipids, biotin-cholesterol, multivalent biotin clusters, streptavidin, and NeutrAvidin — all available for rapid project startup without waiting on external suppliers.
Specialized Design and Synthesis TeamOur chemists handle biotin-lipid conjugate design, PEG spacer selection, valency engineering, and coupling route optimization in-house, so your targeting ligand is purpose-built for your SMVT-expressing cell model rather than adapted from off-the-shelf components.
Fast Global DeliveryWith offices and laboratories across multiple regions worldwide, we coordinate project execution and shipping through the site closest to you, cutting transit times and keeping your biotin-LNP development on schedule.
Cost-Effective DevelopmentVertical integration from ligand synthesis to LNP formulation and cell-based validation means fewer subcontractor markups and faster handoffs — delivering biotin-LNP projects at a total cost that typically undercuts equivalent multi-vendor workflows.
Integrated Full-Workflow ServiceBiotin ligand design, LNP preparation, surface coupling, physicochemical characterization, and SMVT-targeted cell evaluation are all handled under one roof — no gaps, no coordination delays, no mismatch between what was promised and what was delivered.
Biotin-modified LNP development is commonly used when researchers need a flexible surface-engineering strategy for ligand screening, affinity capture, cell uptake tracking, targeted delivery evaluation, or modular nanoparticle functionalization. By introducing biotin groups onto the LNP surface, researchers can use the strong biotin–streptavidin interaction to attach streptavidin-conjugated antibodies, peptides, aptamers, glycans, fluorescent probes, or other functional molecules. This approach is especially useful in early-stage formulation studies because different surface ligands can be compared without completely rebuilding the core LNP formulation each time. It can support studies involving mRNA, siRNA, protein, peptide, small molecule, or imaging payloads, helping researchers evaluate whether surface modification improves cellular interaction, uptake efficiency, intracellular localization, or payload activity in relevant research models.
Biotin-lipid selection should be based on the LNP composition, payload type, intended surface exposure, coupling format, and downstream biological readout. Common options include Biotin-PEG-lipid, Biotin-DSPE, Biotin-cholesterol, and other biotin-bearing lipid anchors. The lipid anchor determines how stably the biotin component associates with the LNP membrane, while the PEG spacer length affects whether the biotin group is accessible to streptavidin or streptavidin-linked ligands. A short spacer may keep the biotin too close to the particle surface, reducing binding accessibility, whereas an overly long spacer may alter the hydration layer and influence cellular interaction. Researchers usually need to compare several biotin-lipid structures, insertion methods, and molar ratios to identify a design that maintains particle quality while providing sufficient surface functionality.
Yes. Biotin density is one of the most important variables in biotin-modified LNP development. If the density is too low, streptavidin binding or ligand attachment may be insufficient, resulting in weak functionalization, poor signal intensity, or limited improvement in cell uptake. If the density is too high, the particle surface may become crowded, causing increased particle size, higher PDI, aggregation, reduced colloidal stability, or altered interaction with cells. For this reason, researchers often screen low, medium, and high biotin-lipid ratios and evaluate them together with particle size, PDI, zeta potential, payload encapsulation, affinity-binding capacity, and cell-based functional readouts. The goal is not simply to maximize biotin density, but to identify a practical balance between ligand accessibility, particle stability, payload retention, and biological performance.
Surface biotin display can be confirmed through a combination of affinity-binding assays, physicochemical characterization, and functional testing. Researchers often use fluorescent streptavidin binding, HABA displacement assays, ELISA-like binding formats, flow cytometry, fluorescence-based particle analysis, or affinity capture methods to evaluate whether biotin groups are accessible on the LNP surface. At the same time, particle size, PDI, zeta potential, payload retention, and formulation stability should be measured before and after biotin modification to ensure that apparent binding signals are not caused by aggregation or nonspecific adsorption. In cell-based studies, useful controls may include unmodified LNPs, biotin-modified LNPs, streptavidin-bridged LNPs, and ligand-conjugated LNPs. These controls help distinguish the contribution of biotin display, streptavidin bridging, and the final targeting ligand.
Common challenges in biotin-modified LNP development include insufficient biotin exposure, particle enlargement after streptavidin bridging, aggregation after ligand attachment, reduced payload activity, unclear targeting contribution, and strong nonspecific binding. In some formulations, biotin groups may be partially hidden by PEG layers or embedded too close to the lipid surface, limiting streptavidin accessibility. In other cases, excessive biotin density or bulky streptavidin-ligand complexes may destabilize the LNP surface and increase PDI. Researchers may also observe stronger cellular uptake without a corresponding increase in mRNA expression, siRNA knockdown, protein activity, or imaging signal localization, indicating that intracellular delivery remains a bottleneck. A well-designed development workflow should optimize biotin-lipid ratio, spacer length, insertion method, ligand-bridging conditions, control groups, and functional readouts together rather than treating surface biotinylation as an isolated modification step.
